David Robert Spring

Title: David Robert Spring: Inventor of CK2α Inhibitor Compounds.

Introduction

David Robert Spring is an inventor based in Cambridge, Great Britain. His patent work is associated with Cambridge Enterprise Limited and focuses on compounds designed to inhibit Casein Kinase 2 alpha (CK2α).

Latest Patents

Spring is associated with 1 patent: “Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof.” The patent describes compounds and their salts, hydrates, and solvates that inhibit CK2α. It also covers pharmaceutical compositions, methods for synthesizing the compounds, and their potential therapeutic uses.

The disclosed compounds are proposed for treating or preventing conditions in which CK2α activity is implicated. These include proliferative disorders such as cancer, viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration, and conditions involving circadian-rhythm regulation.

Career Highlights

Spring’s listed patent connects his inventive work with Cambridge Enterprise Limited, an organization associated with commercializing research and intellectual property. The patent’s scope spans compound design, pharmaceutical compositions, synthesis, and potential therapeutic applications.

Collaborations

The listed coworkers associated with Spring include Marko Juhana Hyvonen and Paul Brear. Their names appear alongside the patent information, although the available details do not specify their individual contributions.

Conclusion

David Robert Spring’s patent activity centers on CK2α-inhibiting compounds and their potential pharmaceutical applications, reflecting a research-focused contribution to therapeutic innovation.